| Name | Title | Contact Details |
|---|
At Senderra, Patients are people. It`s that simple. We are a specialty pharmacy, but that is where our work begins. We believe success lies in service to others. For this reason, we are dedicated to never losing sight of the people. We believe in the power of technology and data as catalysts to transform and improve processes. Technology is a tool to make our lives easier. For this reason, Senderra invests in our unique technology-driven platform in order to perform best at every turn. Finally, we believe in improved outcomes, no matter with whom we work. That includes Patients, Prescribers, Pharma and Payors. Improving outcomes means we strive to make the kinds of differences that matter.
Processo Partners, In is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Shire, we enable people with life altering conditions to lead better lives. We focus on developing and delivering innovative treatments for patients with rare diseases and other specialty conditions.To realize our aspiration to become a leading global biotech, our efforts are concentrated on four key strategic drivers: growth, innovation, efficiency, and people. Our priorities are to drive optimal performance of our existing products, increase patient access to these medicines, and to build our pipeline through research and development and partnerships in order to deliver new medicines to patients.
Norbrook® is a true innovator and dedicated to novel research and revolutionary processes and products. Lord Ballyedmond, Founder, Chairman and CEO of the Norbrook Group began his career in the pharmaceutical industry in the USA in the 1960s and now controls the largest privately owned pharmaceutical company in the world. The company is very active in both medical and veterinary products. Research and Development is the key to Norbrook`s success with the R&D Department central to the company`s structure. It is responsible for new product development, technical support and meeting regulatory and licensing protocols. Norbrook invests more than 10% of its turnover annually in research and development of new products. The company is at the forefront of formulation technology and has developed many new chemical routes for the synthesis of active materials. Norbrook has formulated and registered more than 800 products in 120 countries. The on-going success of the company is conditional on the expertise, knowledge and innovation of the staff employed. Norbrook prides itself on attracting the highest calibre of individual to the company and boasts a multi-national workforce committed to constantly pushing the boundaries and challenging technologies to ensure that Norbrook remains the leading force in pharmaceuticals that it is today.